Physician profile
Sherri Peace
NPI 1962549279
$13,766.56
in general payments reported to CMS, 2019-2025
28 companies · $2,871 in 2025
The $2,871 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $122 · 2021: $155 · 2022: $1,100 · 2023: $3,376 · 2024: $5,098 · 2025: $2,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,235.06 |
| Education | $110.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,877.49 | 2019-2025 | |
| Genzyme Corporation | $1,258.40 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,169.84 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $971.40 | 2023-2024 | Vtama |
| Amgen INC. | $771.96 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $745.20 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $739.70 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $537.79 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $450.68 | 2024-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $434.20 | 2019-2025 | |
| Lilly USA, LLC | $426.21 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $426.00 | 2022-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $344.54 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $302.18 | 2023-2025 | Winlevi, Odomzo, Blu-U |
| Janssen Biotech, INC. | $254.81 | 2019-2025 | Tremfya |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $196.82 | 2023-2025 | Ycanth |
| Dermira, INC. | $191.00 | 2019-2020 | |
| Celgene Corporation | $119.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $105.75 | 2023-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $100.53 | 2019-2025 | Cabtreo, Jublia |
| Galderma Laboratories, L.P. | $98.80 | 2019-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.34 | 2023-2024 | Spevigo |
| Lnhc, INC | $44.10 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $29.10 | 2022-2023 | |
| Kyowa Kirin, INC. | $29.06 | 2023 | Poteligeo |
| Strata Skin Sciences, INC. | $26.87 | 2023 | Xtrac |
| Organon LLC | $21.30 | 2025 | Vtama |
| Botanix Sb INC | $18.67 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherri Peace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.